24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: Race and Gender May Tip the Scales on Traditional Stroke Risk FactorsMeasles Complications Can Affect Every Organ: StudyBabies' Exposure to Household Cleaning Products Tied to Later Asthma RiskCoronavirus: Are U.S. Hospitals Prepared?14 Americans From Cruise Ship Hit By Coronavirus Test Positive for InfectionHot Chocolate Could Help Ease Painful Clogged Leg VesselsAntiviral Drug, Plasma Transfusions Show Promise in Treating CoronavirusHow to Dispel Your Child's Fears About the New CoronavirusCholesterol Drugs Might Help Curb 'High-Risk' Prostate CancersCoronavirus Spreads Most Easily When Patients Are Sickest: CDCWill Brushing and Flossing Protect You Against Stroke?Young Black Adults More Prone to Stroke, but Don't Know ItAHA News: Stroke Rates Down for Mexican Americans, Up for White AdultsCoronavirus Cases, Deaths Rise Sharply, While 2 New Cases Reported in U.S.Scientists Spot Antibody That Might Help Diagnose, Treat Autoimmune DisordersCoronavirus in America: Keep Your Panic in CheckCoronavirus Spread Slows, But Death Toll Jumps to 1,113Growing Up in U.S. 'Stroke Belt' Bad for the Brain Later in LifeShingles Vaccine Bonus: Reduced Risk of Stroke?Air Pollution Made in One State Can Cause Deaths in OthersWere You Born in an H1N1 Flu Year or an H3N2? It MattersStricter Clean Air Laws Could Save Thousands of Lives a Year: StudyCoronavirus Fears Have U.S. Pharmacies Running Out of Face MasksCoronavirus Death Toll Tops 1,000, While 13th U.S. Case ConfirmedMeds May Not Prevent Migraines in KidsHigh Testosterone Levels Have Different Health Impact for Men and WomenCoronavirus Cases Top 40,000, While Deaths Hit 908With Macular Degeneration, 1 Missed Visit to Eye Doc Can Mean Vision LossHundreds Suspected, 12 Confirmed: How CDC Identified U.S. Coronavirus CasesFor Patients on Blood Thinners, GI Bleeding May Signal Colon Cancer: StudyStudy Finds 'No Clear Rationale' for 45% of Antibiotic PrescriptionsThere's a Virus Spreading in U.S. That's Killed 10,000: The FluSome U.S. Workers Are Bringing Toxins Home to Their KidsAHA News: Expert Heart Advice for Rare Genetic Muscle Disorder9/11 Study Shows PTSD Tied to Earlier DeathWorkers With Cluster Headaches Take Twice as Many Sick DaysMore Americans to Be Evacuated From China; 12th Coronavirus Case ReportedYoung-Onset Parkinson's May Start in the Womb, New Research SuggestsHealthy Habits Can Slide After Starting Heart MedicationsWide Variations Found in 'Normal' Resting Heart RateLab Discovery Offers Promise for Treating Multiple SclerosisIs Vaping a Scourge on Your Skin?Many Can Suffer Facial Paralysis -- and Its Emotional TollAHA News: Persistent Asthma Linked to Increased Risk for Heart Rhythm DisorderAs Health Experts Fear Possible Pandemic, 2nd Death Reported Outside ChinaBedside 'Sitters' May Not Prevent Hospital FallsFirst Drug Approved for Treatment of Peanut Allergy in ChildrenAHA News: Millions Are Learning to Live With Heart FailureDoes Race Play a Part in ICU Outcomes?Meat Still Isn't Healthy, Study Confirms
Questions and AnswersLinks
Related Topics

Diabetes

Drug Approved to Treat Tenosynovial Giant Cell Tumor


HealthDay News
Updated: Aug 5th 2019

new article illustration

MONDAY, Aug. 5, 2019 (HealthDay News) -- Turalio (pexidartinib) capsules have been approved to treat adults with symptomatic tenosynovial giant cell tumor (TGCT), the U.S. Food and Drug Administration announced.

The drug was approved for patients with TGCT with severe morbidity or functional limitations that has not improved with surgery. Turalio is only available through the Risk Evaluation and Mitigation Strategy Program.

Approval was based on data from a multicenter international clinical trial of 120 patients. After 25 weeks, patients who received Turalio had a statistically significant improvement in overall response rate (ORR) to an ORR of 38 percent versus no response in patients who received placebo. Fifteen percent of patients had a complete response and 23 percent had a partial response. Among patients followed for a minimum of six months following initial response, 22 of 23 patients maintained their response for six months or longer; all 13 patients who initially responded and were followed for a minimum of 12 months maintained their response for 12 months or longer.

Commonly reported side effects include lactate dehydrogenase, increased aspartate aminotransferase, loss of hair color, increased alanine aminotransferase, and increased cholesterol. Side effects also include neutropenia, increased alkaline phosphatase, decreased lymphocytes, eye edema, decreased hemoglobin, rash, dysgeusia, and decreased phosphate. A Boxed Warning on the prescription information for Turalio warns about the risk for serious and potentially fatal liver injury and advises health care professionals to monitor patients' liver tests before and during treatment and to alter or discontinue use of the drug if liver tests are abnormal.

Approval was granted to Daiichi Sankyo.

More Information